Summary
Gonadorelin is synthetic gonadotropin-releasing hormone, the hypothalamic decapeptide that tells the pituitary to release LH and FSH. Delivered in pulses every 60 to 120 minutes by a portable pump it restores ovulation in most women with hypothalamic amenorrhea and induces sperm production in men with hypogonadotropic hypogonadism, which is how the discontinued approved products (Factrel for diagnosis, Lutrepulse for ovulation induction) were used. The compounded gonadorelin that telehealth clinics prescribe as a few subcutaneous injections per week alongside testosterone, replacing hCG after hCG became a biologic in 2020, has no trial evidence and is pharmacologically doubtful because gonadorelin's half-life is only a few minutes.
What is Gonadorelin?
Gonadorelin is a synthetic decapeptide identical to native human gonadotropin-releasing hormone. It is also known as GnRH, Gonadotropin-releasing hormone, LHRH, Gonadorelin acetate, Gonadorelin hydrochloride, Factrel, Lutrepulse.
How does it work?
Gonadorelin binds GnRH receptors on pituitary gonadotroph cells and triggers release of LH and FSH, which stimulate testicular testosterone production and spermatogenesis or ovarian follicle development. The pituitary responds only to pulsatile GnRH: continuous or high dose exposure downregulates the receptor and suppresses gonadotropins, which is how GnRH agonists such as leuprolide work. Its plasma half-life is about 2 to 4 minutes, so a single subcutaneous injection produces a brief LH pulse rather than sustained stimulation.
| Cluster | Sexual health and reproductive |
|---|---|
| Routes | Subcutaneous or intravenous pulsatile infusion by portable pump (evidence based use); Single subcutaneous or intravenous injection for pituitary function testing (former diagnostic use); Intermittent subcutaneous injections 2 to 3 times weekly (compounded TRT adjunct, no studies) |
| Conditions studied | Male hypogonadism (low testosterone); Infertility and assisted reproduction |
| Record | v3, draft, verified Sep 23, 2026 |
What does the evidence say about Gonadorelin?
Pulsatile GnRH by pump has decades of clinical evidence, mostly observational. A 2018 systematic review and meta-analysis of 35 studies (3 randomized, 32 observational; 1,002 women) with hypothalamic amenorrhea found high ovulation rates, comparable results for subcutaneous and intravenous delivery, and a low incidence of mild ovarian hyperstimulation. In men with hypogonadotropic hypogonadism, a 42 patient series found pulsatile GnRH and hCG plus hMG equally effective, inducing sperm in 54 of 57 treatment courses and pregnancy in 26 of 36. There is no published study of intermittent subcutaneous gonadorelin injections 2 to 3 times per week as an adjunct to testosterone therapy.
| Evidence type | Indexed studies | Participants (human) |
|---|---|---|
| Human randomized trials | 0 | n/a |
| Human observational studies | 4 | 1044 |
| Animal studies | 0 | n/a |
| All indexed studies | 4 | 1,044 |
Human evidence
Tranoulis 2018: systematic review and meta-analysis of pulsatile GnRH in 1,002 women with idiopathic or functional hypothalamic amenorrhea across 35 studies; high ovulation rates, trend toward high pregnancy and live birth rates per ovulatory cycle, low and mild ovarian hyperstimulation, slightly elevated multiple gestation versus the general population. Quaas 2022: 25 year single center cohort of pulsatile GnRH in functional hypothalamic amenorrhea reporting monofollicular ovulation and high cumulative live birth rates. Büchter 1998: 42 men with hypogonadotropic hypogonadism treated with pulsatile GnRH or hCG/hMG; testicular volume doubled within 5 to 12 months, sperm appeared in 54 of 57 courses, pregnancies in 26 of 36, with no significant difference between GnRH and gonadotropins. Dwyer 2024: review of fertility induction in congenital hypogonadotropic hypogonadism summarizing pulsatile GnRH and gonadotropin regimens.
Animal evidence
GnRH was isolated and sequenced from porcine and ovine hypothalami in 1971; primate studies by Knobil's group established that pulsatile but not continuous GnRH sustains gonadotropin secretion, the principle that underlies all pump protocols. Veterinary gonadorelin products are approved for cattle reproduction.
Key studies
| Study | Design and population | Outcome | Grade |
|---|---|---|---|
| Efficacy and safety of pulsatile gonadotropin-releasing hormone therapy among patients with idiopathic and functional hypothalamic amenorrhea: a systematic review of the literature and a meta-analysis2018 PMID 29605411 | Systematic review and meta-analysis of 35 studies (3 randomized, 32 observational)n = 1,002 Women with idiopathic or functional hypothalamic amenorrhea treated with pulsatile GnRH | High ovulation rates, trend toward high pregnancy and live birth rates per ovulatory cycle, comparable subcutaneous and intravenous results, low and mild ovarian hyperstimulation | Evidence: Human observational evidence |
| Use of pulsatile gonadotropin-releasing hormone (GnRH) in patients with functional hypothalamic amenorrhea (FHA) results in monofollicular ovulation and high cumulative live birth rates: a 25-year cohort2022 PMID 36378460 | Single center retrospective cohort over 25 yearsWomen with functional hypothalamic amenorrhea treated with pulsatile GnRH | Predominantly monofollicular ovulation and high cumulative live birth rates | Evidence: Human observational evidence |
| Pulsatile GnRH or human chorionic gonadotropin/human menopausal gonadotropin as effective treatment for men with hypogonadotropic hypogonadism: a review of 42 cases1998 PMID 9758439 | Single center case seriesn = 42 Men with idiopathic hypogonadotropic hypogonadism, Kallmann syndrome, or hypopituitarism | Testicular volume doubled within 5 to 12 months; sperm induced in 54 of 57 courses; pregnancy in 26 of 36 courses; no significant difference between pulsatile GnRH and hCG/hMG | Evidence: Human observational evidence |
| Current landscape of fertility induction in males with congenital hypogonadotropic hypogonadism2024 PMID 39190467 | Narrative reviewMen with congenital hypogonadotropic hypogonadism | Summarizes pulsatile GnRH and gonadotropin regimens, predictors of response, and the need for pulsatile delivery | Evidence: Human observational evidence |
Conditions studied
| Condition | Grade | Note |
|---|---|---|
| Male hypogonadism (low testosterone) | Evidence: Human observational evidence | Pulsatile GnRH induced sperm in 54 of 57 treatment courses in men with hypogonadotropic hypogonadism, similar to hCG plus hMG; branded US products were discontinued. |
| Infertility and assisted reproduction | Evidence: Human observational evidence | In over 1,000 women with hypothalamic amenorrhea, pulsatile GnRH produced high ovulation rates with little hyperstimulation; branded US products were discontinued. |
Is Gonadorelin legal in the United States?
FDA and compounding status
Gonadorelin was the active ingredient of two FDA approved human products, Factrel (gonadorelin hydrochloride, a diagnostic for pituitary function) and Lutrepulse (gonadorelin acetate for pump delivered ovulation induction), both of which have been discontinued in the United States for commercial rather than safety reasons. Because it is a component of FDA approved drugs, 503A pharmacies can compound it under a prescription, which is why it is widely available as a compounded testosterone therapy adjunct. As a 10 amino acid peptide it was not affected by the March 2020 transition of hCG and other large proteins to biologic status, so it filled the gap when compounded hCG became unavailable. It is not on the FDA Category 2 list. The currently marketed FDA approved gonadorelin products are veterinary.
WADA status
WADA prohibited. Athletes subject to anti-doping testing should treat this as prohibited at all times unless the current prohibited list says otherwise.
Regulatory timeline
- WADA
WADA publishes the 2027 Prohibited List
WADA published the 2027 Prohibited List on September 21, 2026, and it takes effect January 1, 2027. The S2 peptide hormone and growth factor classes are unchanged. BPC-157 is still named under S0, and MOTS-c is still named under S4.4 as an activator of AMP-activated protein kinase. WADA added a note that many peptides without approval for human use fall under S0 or another section, and that a peptide not named on the list may still be prohibited. GLP-1 receptor agonists such as semaglutide and tirzepatide are still not on the list.
- WADA
WADA 2026 Prohibited List takes effect
The 2026 WADA Prohibited List took effect on January 1, 2026 and continues to prohibit the S2 peptide hormone and growth factor classes (GHRH analogs, growth hormone secretagogues, GH fragments, IGF-1 and analogs, MGF, thymosin beta-4 and derivatives, hCG and GnRH-class releasing factors in males), myostatin inhibitors, insulin and the AMPK activator MOTS-c under S4, desmopressin under S5, and BPC-157 under S0. GLP-1 receptor agonists such as semaglutide and tirzepatide are not on the list.
- WADA
WADA 2025 Prohibited List keeps peptide hormones and growth factors banned at all times
The 2025 WADA Prohibited List took effect on January 1, 2025. Section S2 (peptide hormones, growth factors, related substances and mimetics) covers GHRH analogs such as CJC-1295, sermorelin, and tesamorelin, growth hormone secretagogues such as ipamorelin, GHRP-2, GHRP-6, hexarelin, and ibutamoren (MK-677), growth hormone fragments such as AOD-9604, growth factors including IGF-1 and its analogs, MGF, and thymosin beta-4 (TB-500), and chorionic gonadotropin and releasing factors such as gonadorelin and kisspeptin (prohibited in males). Myostatin inhibitors such as ACE-031 fall under S4, insulin under S4 metabolic modulators, desmopressin under S5, and BPC-157 remains an S0 non-approved substance.
Gonadorelin dosing: FDA label and trial doses
Doses below are quoted from the FDA label for its approved uses, plus the doses used in the pivotal trials where noted. The prescriber sets the dose; PeptideAgent does not recommend doses or protocols.
Pulsatile pump protocols in the literature and the former Lutrepulse label: 5 mcg gonadorelin acetate intravenously every 90 minutes (range 1 to 20 mcg per pulse) for ovulation induction, with subcutaneous pulses of similar size every 60 to 120 minutes used in many series; men with hypogonadotropic hypogonadism received subcutaneous pulses every 2 hours for months. Diagnostic use (former Factrel label): a single 100 mcg subcutaneous or intravenous dose to test pituitary LH response. No literature dosing exists for intermittent injections 2 to 3 times per week.
Routes reported
| # | Route |
|---|---|
| 1 | Subcutaneous or intravenous pulsatile infusion by portable pump (evidence based use) |
| 2 | Single subcutaneous or intravenous injection for pituitary function testing (former diagnostic use) |
| 3 | Intermittent subcutaneous injections 2 to 3 times weekly (compounded TRT adjunct, no studies) |
What are the side effects and interactions of Gonadorelin?
Side effects
| # | Reported side effect |
|---|---|
| 1 | Injection or infusion site reactions, including inflammation and, with intravenous pumps, rare thrombophlebitis |
| 2 | Headache, nausea, abdominal discomfort, flushing, lightheadedness reported with diagnostic doses |
| 3 | Ovarian hyperstimulation syndrome (uncommon and mild with pulsatile therapy) and multiple pregnancy |
| 4 | Hypersensitivity reactions including anaphylaxis (rare) |
| 5 | Antibody formation against gonadorelin reported with prolonged use |
| 6 | Paradoxical suppression of LH and FSH if given continuously or at high frequency |
Interactions
| # | Interaction |
|---|---|
| 1 | Androgens, estrogens, progestins, and glucocorticoids blunt the pituitary response and confound diagnostic testing |
| 2 | Dopamine antagonists, spironolactone, levodopa, and oral contraceptives can alter gonadotropin response to diagnostic doses |
| 3 | GnRH agonists and antagonists (leuprolide, ganirelix, cetrorelix) block or override its effect |
| 4 | Testosterone therapy suppresses the axis gonadorelin is meant to stimulate; the combination has not been studied |
Contraindications
| # | Contraindication |
|---|---|
| 1 | Hypersensitivity to gonadorelin or components |
| 2 | Pregnancy (former Lutrepulse label: discontinue once pregnancy is confirmed) |
| 3 | Conditions that could be worsened by ovarian stimulation, such as ovarian cysts or undiagnosed vaginal bleeding |
| 4 | Hormone dependent tumors (theoretical, via sex steroid stimulation) |
| 5 | Male athletes subject to WADA testing (prohibited under S2) |
How do people access Gonadorelin legally?
Typical cost: Compounded gonadorelin is usually priced per vial: 50 USD per vial as an add-on in a telehealth testosterone program whose fee is separate. Pulsatile pump therapy for infertility is delivered through reproductive endocrinology clinics, where the drug is a small part of the total cost of treatment. Prices checked 2026-09-22 on published provider and pharmacy price pages.
Verified access options
Step 1
Prescription from a reproductive endocrinologist with a portable infusion pump for ovulation or spermatogenesis induction (compounded drug, since the approved products are discontinued).
Step 2
Prescription filled by a 503A compounding pharmacy as subcutaneous vials, usually through testosterone telehealth clinics.
Step 3
Not available as an FDA approved human product at present.
Access paths are verified against public regulatory records and prescriber licensing. We never list unlicensed vendors.
Compare Gonadorelin
Frequently asked questions
Is gonadorelin legal in the United States?
Yes, by prescription. Gonadorelin was the active ingredient of the FDA approved human products Factrel and Lutrepulse, which were discontinued for commercial reasons, and that approval history lets 503A pharmacies compound it under a prescription. It is not on the FDA Category 2 list. Testosterone clinics prescribe it widely, although the way they use it has not been studied. [6] [7] [8]
Does gonadorelin work as an hCG replacement on TRT?
Nobody has tested it. Clinics switched from hCG to gonadorelin after hCG became a biologic in 2020 and could no longer be compounded. hCG has at least retrospective data showing it preserves sperm production during testosterone therapy, but gonadorelin's half-life is a few minutes and it only stimulates the pituitary when delivered in pulses every 1 to 2 hours; two or three injections a week produce brief LH blips at best. No study has measured testicular volume, sperm counts, or testosterone recovery with that regimen. [3] [5] [7]
Does gonadorelin work for fertility?
When delivered in pulses by a pump, yes. A meta-analysis of 1,002 women with hypothalamic amenorrhea found high ovulation rates, mostly single pregnancies, and little ovarian hyperstimulation. In 42 men with hypogonadotropic hypogonadism, pulsatile GnRH or hCG plus hMG induced sperm production in 54 of 57 treatment courses and pregnancies in 26 of 36, with no difference between the two approaches. This requires a pump worn continuously for months, not weekly injections. [1] [3]
What are the side effects of gonadorelin?
Diagnostic doses caused headache, nausea, flushing, abdominal discomfort, and injection site reactions. Pump therapy adds infusion site inflammation and, with intravenous pumps, occasional thrombophlebitis; ovarian hyperstimulation is uncommon and mild, and multiple pregnancy is slightly more likely than in the general population. Rare hypersensitivity and antibody formation have been reported. Giving it continuously or too often suppresses rather than stimulates the axis. [1] [6]
How is gonadorelin taken and what dose was studied?
The evidence based regimen is a portable pump delivering about 5 mcg (range 1 to 20 mcg) intravenously every 90 minutes, or similar subcutaneous pulses every 60 to 120 minutes, for as long as it takes to ovulate or produce sperm. The diagnostic test was a single 100 mcg injection. The compounded 2 to 3 times weekly subcutaneous schedule sold by clinics has no literature dose. [1] [4]
How much does gonadorelin cost?
Compounded gonadorelin is usually sold per vial: 50 USD per vial as an add-on in a telehealth testosterone program, whose program fee is separate. Pump therapy for infertility is arranged through reproductive endocrinology clinics and the drug is a minor part of the overall cost. Prices checked 2026-09-22. [6] [10]
Is gonadorelin banned by WADA?
Yes, for male athletes. The WADA Prohibited List names gonadorelin explicitly in section S2 as a releasing factor for chorionic gonadotropin and LH, prohibited in males at all times. It is not prohibited in females. A therapeutic use exemption would be needed for any legitimate medical use by a male athlete. [9]
Gonadorelin vs hCG: which is better?
For inducing sperm production in hypogonadotropic men they performed equally in a 42 patient series, but gonadorelin needs a pump and hCG is injected 2 to 3 times a week, which is why hCG was the practical choice for decades. hCG has retrospective evidence for preserving sperm during testosterone therapy; gonadorelin has none. Since 2020 hCG is a biologic that cannot be compounded, so brand hCG is the only lawful hCG, while gonadorelin can be compounded. Both are prohibited for male athletes. [3] [5] [7]
Decisions about starting, stopping, or combining any treatment belong with a licensed clinician who knows your history.
From the blog
- Peptides for men, ranked by human evidence
hCG, GLP-1 drugs, teriparatide, and tesamorelin have human trials and a lawful route. PT-141 is off-label for men, and kisspeptin and melanotan II have no lawful path. Ranking, legality, and WADA.
- Peptides for women, ranked by human evidence
GLP-1 drugs, teriparatide, abaloparatide, and Vyleesi (PT-141) have real trials in women. Kisspeptin is research-only and GHK-Cu rests on small skin studies. The ranking and legal status.
Sources
Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.
- [1]Tranoulis A et al. Efficacy and safety of pulsatile gonadotropin-releasing hormone therapy among patients with idiopathic and functional hypothalamic amenorrhea: a systematic review of the literature and a meta-analysis. Fertil Steril 2018PubMed 29605411, 2018
- [2]Quaas P et al. Use of pulsatile GnRH in patients with functional hypothalamic amenorrhea results in monofollicular ovulation and high cumulative live birth rates: a 25-year cohort. J Assist Reprod Genet 2022PubMed 36378460, 2022
- [3]Buchter D et al. Pulsatile GnRH or human chorionic gonadotropin/human menopausal gonadotropin as effective treatment for men with hypogonadotropic hypogonadism: a review of 42 cases. Eur J Endocrinol 1998PubMed 9758439, 1998
- [4]Dwyer AA et al. Current landscape of fertility induction in males with congenital hypogonadotropic hypogonadism. Ann N Y Acad Sci 2024PubMed 39190467, 2024
- [5]Hsieh TC et al. Concomitant intramuscular human chorionic gonadotropin preserves spermatogenesis in men undergoing testosterone replacement therapy. J Urol 2013PubMed 23260550, 2013
- [6]Drugs@FDA database (search gonadorelin for the discontinued Factrel and Lutrepulse approvals)FDA, 2026
- [7]FDA: Compounding and the FDA, questions and answers (including that biological products cannot be compounded under 503A or 503B)FDA, 2026
- [8]FDA: Certain bulk drug substances for use in compounding that may present significant safety risks (Category 2 list and withdrawn nominations, current as of April 22, 2026)FDA, 2026
- [9]WADA Prohibited List, section S2 peptide hormones, growth factors, related substances and mimeticsWADA, 2026
- [10]Licensed telehealth provider price page for compounded gonadorelin, accessed 2026-09-22
Cite this page
Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.
- APA style
PeptideAgent. (2026, September 23). Gonadorelin: evidence, legality, and access. https://peptideagent.ai/peptides/gonadorelin- HTML link
<a href="https://peptideagent.ai/peptides/gonadorelin">Gonadorelin: evidence, legality, and access</a>, PeptideAgent, updated September 23, 2026.